Surgery Partners Inc
$ 14.08
1.15%
04 Mar - close price
- Market Cap 1,800,438,000 USD
- Current Price $ 14.08
- High / Low $ 14.65 / 13.73
- Stock P/E N/A
- Book Value 13.38
- EPS -1.36
- Next Earning Report 2026-05-05
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.04 %
- ROE 0.03 %
- 52 Week High 24.64
- 52 Week Low 12.25
About
Surgery Partners, Inc. owns and operates a network of surgical facilities and ancillary services in the United States. The company is headquartered in Brentwood, Tennessee.
Analyst Target Price
$22.77
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-03-02 | 2025-11-10 | 2025-08-05 | 2025-05-05 | 2025-02-24 | 2024-11-12 | 2024-08-06 | 2024-05-07 | 2024-02-26 | 2023-11-07 | 2023-08-01 | 2023-05-01 |
| Reported EPS | 0.12 | 0.13 | -0.02 | 0.04 | 0.44 | -0.2512 | 0.21 | 0.1 | 0.44 | 0.19 | 0.28 | 0.08 |
| Estimated EPS | 0.3038 | 0.21 | 0.16 | 0.07 | 0.3769 | 0.25 | 0.2 | 0.07 | 0.38 | 0.16 | 0.08 | 0.01 |
| Surprise | -0.1838 | -0.08 | -0.18 | -0.03 | 0.0631 | -0.5012 | 0.01 | 0.03 | 0.06 | 0.03 | 0.2 | 0.07 |
| Surprise Percentage | -60.5003% | -38.0952% | -112.5% | -42.8571% | 16.7418% | -200.48% | 5% | 42.8571% | 15.7895% | 18.75% | 250% | 700% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-05 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | -0.0187 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: SGRY
2026-03-04 21:51:52
Jefferies maintained a Buy rating on Surgery Partners (SGRY) on March 4, 2026, though it lowered its price target to $16.25 due to updated assumptions after Q4 results and 2026 guidance. Alongside Cantor Fitzgerald and RBC Capital, who also reiterated positive stances but trimmed targets, the move signaled continued analyst confidence in SGRY's recovery potential despite near-term revenue and payer-mix concerns. Investors are advised to monitor guidance execution and cash flow trends.
2026-03-04 20:51:52
Surgery Partners (NASDAQ: SGRY) has acquired Preferred Vascular Group (PVG), an operator of ambulatory surgical centers specializing in dialysis access procedures. This acquisition gives Surgery Partners entry into the $6 billion dialysis access market, adding eight ASCs in Georgia and Ohio and retaining PVG's management team. Ziegler acted as the exclusive financial advisor for PVG in this transaction.
2026-03-04 16:00:00
Ziegler, a specialty investment bank, served as the exclusive financial advisor to Preferred Vascular Group (PVG) on its acquisition by Surgery Partners. PVG specializes in dialysis access procedures with eight Ambulatory Surgical Centers (ASCs) in Georgia and Ohio, filling a critical gap in dialysis care. This acquisition positions Surgery Partners to enter the $6 billion dialysis access market and leverage PVG's vascular expertise across its surgical centers, with PVG's management team continuing to lead for national scaling.
2026-03-04 12:51:52
Surgery Partners, Inc. reported its Q4 and full year 2025 earnings, with full year net revenue of $3.3 billion, up 6.2% year over year, and adjusted EBITDA of $526 million, up 3.5%. The company experienced significant headwinds in the second half of the year, particularly in three surgical hospital markets due to slower case growth, payer mix shifts, and anesthesia dynamics. Despite these challenges, Surgery Partners remains committed to its long-term growth strategy, which includes organic growth, de novo facilities, and acquisitions, while also focusing on portfolio optimization and reducing leverage.
2026-03-04 08:31:00
Johnson Fistel, PLLP is investigating potential claims on behalf of investors of Surgery Partners, Inc. (NASDAQ: SGRY) following the company's Q4 and full-year 2025 financial results, which did not meet expectations and led to a sharp decline in share price. The investigation focuses on whether investor losses can be recovered under federal securities laws. Shareholders who suffered losses are encouraged to contact Johnson Fistel for more information.
2026-03-04 06:01:55
Surgery Partners (SGRY) shares fell 12% following a Q4 EBITDA miss and weak guidance. This sell-off was driven by the market's reaction to the company's financial performance and future outlook. The article highlights investor concerns about Surgery Partners' immediate profitability and growth prospects.
